Tigecycline susceptibility among multi-drug resistant bacteria: A 7-year retrospective study
1 Department of Microbiology, Avicenne Military Hospital, Marrakesh, Morocco.
2 Faculty of medicine and pharmacy of Marrakesh – Cadi Ayyad University, Marrakesh, Morocco.
Research Article
GSC Advanced Research and Reviews, 2022, 11(01), 079–083.
Article DOI: 10.30574/gscarr.2022.11.1.0096
Publication history:
Received on 28 February 2022; revised on 05 April 2022; accepted on 07 April 2022
Abstract:
The emergence and spread of multidrug-resistant bacteria (MDR) are major public health issues worldwide. The objective of this study is to evaluate the microbiological efficacy of tigecycline against multi-drug-resistant bacteria and to explore its potential place in clinical practice. A retrospective study was carried out over 7 years, from January 2015 to December 2021, at the Avicenne Military Hospital. Were collected all bacteriological samples received for diagnostic purposes at the microbiology laboratory. Tigecycline susceptibility was tested among 846 isolates among the 4293 isolates during the study period. The overall frequency of MDR bacteria was of 14,3%. 60% of the MDR bacteria isolated were susceptible, 35% were declared resistant and 5% were declared intermediate. Co-resistance levels in MDR bacteria are high. Tigecycline remained active in vitro on most of the MDR bacteria tested. The susceptibility rates for tigecycline found were respectively 76%, 57%, and 34%, for the ESBL Enterobacteriaceae strains, the CPEs, and the multi-drug resistant Acinetobacter baumanii strains. In this study, the MDR bacteria isolated showed overall satisfying susceptibility rates to tigecycline.
Keywords:
MDR bacteria; Tigecycline; Susceptibility testing; Antibiotics resistance
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
